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aBstraCt
X-linked juvenile retinoschisis (XLRS) is one of the most common X-linked inherited, bilateral vitreoretinal dys-
trophies affecting males in the first two decades of life. In this article, we present a case report of a young man who 
presented with gradual decrease in visual acuity in both eyes that was attributed to macular edema and foveal schisis 
in the inner retinal layers. He was investigated by appropriate ocular images which were consistent with a diagnosis 
of XLRS. He was treated by anti-vascular endothelial growth factor (anti-VEGF) intravitreal injection, dorzolamide 
eye drops and intravitreal steroids injection without improvement. 
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introduCtion
X-linked juvenile retinoschisis (XLRS) is a rela-
tively common early-onset retinal degenerative dis-
ease that affects males early in life [1]. Character-
istic features include mild to severe loss in central 
vision, splitting of inner retinal layers in the fovea 
and in peripheral retina, and a reduction in b-wave 
amplitude in Electroretinogram (ERG) [2]. Cur-
rently, there is no approved treatment for XLRS and 
management involves treating complications, which 
commonly include vitreous hemorrhage and retinal 
detachments [3].
Case report 
Twenty-year-old male patient presented com-
plaining of bilateral gradual painless decrease in 
vision during the last few months. He denied any 
nyctalopia. The patient visited another doctor who 
has diagnosed him with macular edema and treated 
him previously with bilateral anti-VEGF (ranibi-
zumab 0.5 mg/0.05 cc). On examination, the pa-
tient’s best corrected visual acuity of the right eye 
was 0.2 and of the left eye was 0.3. Anterior seg-
ments of both eyes were within normal limits and 
intraocular pressure was 12 mm Hg in each eye. 
Fundus examination (Fig. 1) in both eyes revealed 
blunted foveal reflex, peripheral inferiotemporal 
oval retinoschisis in the form of oval defects and 
retinal veils. Ocular coherent tomography (OCT) 
was done (Fig. 2) which revealed bilateral asym-
metrical foveal cystic spaces and schisis in the in-
ner retinal layer. Fundus Fluorescein Angiography 
(FFA) was done (Fig. 3) and showed bilateral dry 
macula and peripheral hypofluorescence in the area 
of retinal veils. ERG test showed selective decreased 
b-wave response. All of these findings are consist-
ent with XLRS. Because the patient received the 
injection of anti-VEGF 2 months ago without any 
improvement (as demonstrated by comparing the 
OCT before and after the injection), a decision was 
made to start the patient on topical dorzolamide 
eye drop (2%) 3 times a day for 1 month. The 
patient came back with no improvement. A trial 
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of intravitreal injection of preservative free triamci-
nolone (4mg/0.1 cc) was given and the patient was 
followed up for 2 months. The patient came back 
with no improvement also. So a decision was made 
just to follow up the patient. 
disCussion 
X-linked juvenile retinoschisis is the leading 
cause of juvenile macular degeneration in males 
and leads to splitting within the inner retinal lay-
ers leading to visual deterioration [4]. Many mis-
sense and protein truncating mutations have been 
identified in the causative retinoschisis gene (RS1) 
which secrets retinal protein, retinoschisin, which 
is implicated in cell–cell interactions and cell ad-
hesion. Mutations cause loss of retinoschisin and 
consequently loss of its function [5]. 
The name derives from an internal splitting of 
the retina mostly affecting the temporal periphery 
of the fundus which occurs in less than 50% of 
affected individuals, whereas foveal involvement is 
present in all affected patients, which is usually as-
sociated with moderate visual loss [1]. Nevertheless, 
Figure 3. FFa for both eyes showing absence of leakage in the 
macula (left column: left eye, right column: right eye)
Figure 1. Color fundus photograph of both eyes showing the peripheral veils (left: left eye, right: right eye)
Figure 2. oCt of both eyes showing foveal inner layer schisis 
(left column: left eye, right column: right eye)
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these figures vary according to the studied popula-
tion and the mutated gene [6]. 
If the inner sheet of the schisis degenerates, the 
retinal vessels may remain running free through 
the vitreous cavity presenting as so called vitreous 
veils. If additional breaks occur in the outer sheet 
of the schisis, a retinal detachment may occur [1]. 
Vitreous hemorrhage is also a known complication 
resulting from  the rupture of unsupported blood 
vessels or pre-retinal neovascularization [7].
Macular edema in this disease is peculiar because 
of the absence of leakage on FFA, which narrows 
the differential diagnosis to a few diseases, namely, 
some types of retinitis pigmentosa, X-linked retino-
schisis, nicotinic acid maculopathy, and some cases 
of epiretinal membrane and vitreomacular traction 
syndrome [8].
One theoretical mechanism of macular edema 
involves intracytoplasmic edema of Muller cells, 
which may stem from an initial microvascular insult. 
This same process may occur in XLRS, where ab-
normal retinoschisin accumulation causes dysfunc-
tional Muller cells [3]. Based on this theory, many 
attempts have been taken to treat the edema using 
anti-inflammatory medications; one such trial was 
taken successfully by injections of intravitreal triam-
cinolone acetate, dexamethasone implant, intravit-
real fluocinolone acetonide implant [3], and even 
subteneon triamcinolone [9]. Others have tried car-
bonic anhydrase inhibitors, such as dorzolamide and 
acetazolamide [10–12]. In fact, carbonic anhydrase 
inhibitors are thought to enhance adhesion between 
retina and retinal pigment epithelium (RPE). XLRS 
patients with foveal cystic cavities unresponsive to 
or worsening on carbonic anhydrase inhibitors may 
benefit from discontinuation for up-to 6 months 
(“medication vacation”) and later retreatment with 
the same agent. The ON/OFF medication regimen 
is believed to allow the RPE metabolic pump to par-
tially recover and therefore facilitate the ability for 
a future response to treatment [13]. In our patient, 
both of these drugs were used without success.
Although anti-VEGF drugs may be an effective 
and safe way to prevent deterioration of XLRS with 
certain complications such as vitreous hemorrhage 
and exudative retinal detachment [6], it was used in 
this case to treat macular edema without any benefit. 
So, we ended up with a case that is refractory to 
all known medications. We advocated observing the 
patient since then. 
ConClusion 
In conclusion, XLRS is a genetic disease with 
many ocular manifestations which in some pa-
tients were found to respond to pharmacotherapy. 
Patients with refractory edema may be observed 
closely. 
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